Progress in Stem Cell 2025, 12(1):418
Open Access Full Text Article

Editorial

Global effects of Ryoncil: A paradigm shift in science and policy

Phuc Van Pham[1,2,*]

ABSTRACT
The recent approval of remestemcel-L (Ryoncil®) by the United States Food and Drug Administration (FDA) constitutes a watershed event for regenerative medicine. As the first allogeneic mesenchymal stromal cell (MSC) therapy to receive FDA approval, its importance extends well beyond its initial indication for pediatric steroid-refractory acute graft-versus-host disease (SR-aGVHD). In this editorial, we examine the worldwide ramifications of this decision, proposing that Ryoncil's development trajectory and ultimate authorization represent a critical inflection point that establishes a new regulatory paradigm for cell-based therapeutics and transforms the clinical, manufacturing, and policy landscape of the stem-cell field. We discuss the accumulated scientific validation of MSC biology, the stringent regulatory pathway with a strong emphasis on Chemistry, Manufacturing, and Controls (CMC), and the forthcoming challenges of clinical implementation and equitable global access that will determine the future of this therapeutic class.
Key words: Regenerative Medicine, Cell Therapy Regulation, Mesenchymal Stromal Cells (MSCs), FDA Approval, Policy Implications

INTRODUCTION

The field of stem cell therapy has long been poised at the threshold of transformative clinical impact. For decades, mesenchymal stromal cells (MSCs) have been at the forefront of this promise, with thousands of clinical trials investigating their immunomodulatory and regenerative potential[1–3]. However, the transition from experimental intervention to an approved pharmaceutical product has been fraught with challenges, including heterogeneity of cell sources, poorly elucidated mechanisms of action, and a lack of standardized potency assays. The path to regulatory approval has therefore frequently been regarded as a nebulous and insurmountable hurdle.

The FDA's approval of Ryoncil on December 18, 2024, has fundamentally altered the therapeutic landscape[4]. This ruling represents not only the authorization of a novel agent for a severe orphan disease but also the formal validation of an entire scientific and technological platform. For the editors and readers of *Progress in Stem Cell*, this milestone warrants a comprehensive appraisal that extends beyond the immediate clinical endpoints. Accordingly, this editorial will analyze the worldwide implications of Ryoncil's licensure, positioning it as a dual achievement: a therapeutic breakthrough for patients and a regulatory template for the forthcoming generation of cell-based therapies.

THE SCIENTIFIC BREAKTHROUGH: ADDRESSING AN UNMET MEDICAL NEED

The approval of Ryoncil is underpinned by its capacity to address an unmet medical need. Pediatric steroid-refractory acute graft-versus-host disease (SR-aGVHD) is a life-threatening complication of allogeneic hematopoietic stem-cell transplantation, characterized by a dysregulated immune response that targets host tissues[5]. Because responses to systemic corticosteroids are historically poor and subsequent therapeutic options are limited, mortality remains exceedingly high.

Ryoncil is an allogeneic, bone-marrow-derived mesenchymal stromal cell (MSC) product delivered as an off-the-shelf intravenous infusion[5,6]. Rather than engrafting and differentiating, MSCs mediate their effects primarily through paracrine signalling and direct cell-to-cell interactions. Accordingly, Ryoncil secretes multiple bioactive mediators that modulate the inflammatory milieu, attenuate pathogenic T-cell activity, and induce a regulatory immune phenotype. This multifactorial mechanism renders the product a rational therapy for the complex pathophysiology of aGVHD[5].

Pivotal clinical trial data underpinning approval demonstrated substantial clinical benefit. The study reported an Overall Response Rate (ORR) of 70 % at Day 28, including a 30 % Complete Response (CR)

[1]*VNUHCM-US Stem Cell Institute, University of Science, Ho Chi Minh City, Viet Nam*

[2]*Viet Nam National University, Ho Chi Minh City, Viet Nam*

Correspondence

Phuc Van Pham, VNUHCM-US Stem Cell Institute, University of Science, Ho Chi Minh City, Viet Nam

Viet Nam National University, Ho Chi Minh City, Viet Nam

Email: phucpham@sci.edu.vn

History
- Received: 2025-05-30
- Accepted: 2025-06-15
- Published Online: 2025-06-30

DOI : 10.15419/041k1g59

Cite this article : Van Pham P. **Global effects of Ryoncil: A paradigm shift in science and policy**. *Prog. Stem Cell.* 2025; 12(1):418.

rate and a 41 % Partial Response (PR) rate. Critically, the 6-month overall survival rate reached 69 %, a significant improvement in a patient population in which mortality often exceeds 80 % in severe cases[7]. This robust efficacy profile provided compelling evidence for regulatory endorsement, demonstrating that a well-characterized MSC product can consistently modify the course of a complex immune-mediated disease.

THE POLICY PRECEDENT: FORGING A NEW REGULATORY PATHWAY

Although the clinical data were necessary, they proved insufficient for regulatory approval. The regulatory trajectory of Ryoncil constituted a landmark event, establishing a pivotal policy precedent that is expected to inform future applicants for many years.

The Crucible of Regulatory Scrutiny

Ryoncil's development trajectory has been non-linear. It encountered a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA), underscoring the distinctive challenges associated with the regulation of living medicinal products. The agency's refusal was driven not by insufficient clinical efficacy but by Chemistry, Manufacturing, and Controls (CMC) concerns. Specifically, regulators requested additional evidence demonstrating that the product can be manufactured with consistent identity, purity, quality, and potency across all production batches[4]. This episode illustrates a paradigm shift in regulatory science: for cell-based therapeutics, the manufacturing process is inextricably intertwined with the final product.

The Centrality of Potency Assays

The resolution of the Chemistry, Manufacturing, and Controls (CMC) issues represents the most significant regulatory lesson derived from Ryoncil's approval. The sponsor implemented robust, newly developed potency assays, which are quantitative tests that directly measure the biological activity of the product—the attribute most closely linked to its intended clinical effect. For Ryoncil, this entailed demonstrating consistent in vitro immunomodulatory capacity and correlating that activity with clinical outcomes. By establishing and validating these assays, the manufacturer provided the FDA with a batch-specific "biologic fingerprint," thereby ensuring that every lot delivers predictable and reproducible therapeutic potential. Mesoblast company implemented an *in vitro* potency assay to measure the suppression of interleukin-2 receptor α (IL-2Rα) expression on stimulated T cells after co-culture with Ryoncil cells[7,8].

This advancement establishes a new, non-negotiable standard for the sector. Future biologics license applications (BLAs) for mesenchymal stromal cell (MSC) therapies will be expected to include potency assays of similar sophistication and clinical relevance, shifting the field from a descriptive catalogue of surface markers toward a rigorous, function-based product definition.

GLOBAL RIPPLE EFFECTS: RESHAPING CLINICAL PRACTICE AND COMMERCIAL LANDSCAPES

The approval in the United States has immediate and profound implications for clinicians, developers, and healthcare systems worldwide.

Shifting Clinical Paradigms and Expanding Indications

Globally, the standard of care for pediatric steroid-refractory acute graft-versus-host disease (SR-aGVHD) has shifted. Ryoncil now offers a formally approved, protocol-driven therapy, transforming management from one of desperation to one grounded in evidence-based practice. This regulatory endorsement has also catalyzed additional clinical development. A pivotal Phase III trial in adult SR-aGVHD, to be conducted in collaboration with the National Institutes of Health–funded Blood and Marrow Transplant Clinical Trials Network (BMT CTN), is planned . This public–private partnership illustrates how initial approval can leverage large research networks to rapidly enhance clinical knowledge and expand patient access.

Moreover, the therapeutic success achieved in aGVHD has reinvigorated investigation of mesenchymal stromal cells (MSCs) for other immune-mediated disorders, including Crohn's disease, rheumatoid arthritis, and solid-organ transplant rejection. Ryoncil thus serves as a validated platform product whose safety profile and mechanism of action can be evaluated in diverse inflammatory settings.

Navigating the Challenges of Commercialization and Access

As the first therapy of its kind, Ryoncil must confront the unique challenge of integrating an allogeneic, off-the-shelf cellular product into the current healthcare infrastructure. This introduces unprecedented complexities in logistics, reimbursement, and clinician education. The establishment of the MyMesoblast^{TM}

support program represents a proactive strategy to mitigate these barriers. The program assists treatment centers throughout the continuum—from product ordering and cold-chain distribution to insurance pre-authorization navigation and facilitation of patient financial assistance. The model's outcome will be scrutinized by payers and developers, as it may establish a blueprint for the commercialization of future, equally complex cell therapies. The cost-effectiveness of this high-cost intervention, weighed against its potentially life-saving benefits and its capacity to prevent long-term complications, is expected to undergo rigorous pharmacoeconomic evaluation and stimulate debate within healthcare systems worldwide.

FUTURE DIRECTIONS AND UNRESOLVED QUESTIONS

Despite this landmark approval, Ryoncil's authorization raises several critical questions that the field must now address:

Mechanism of action

Although its immunomodulatory capacity is recognized, a more detailed molecular elucidation of how MSCs exert their effects *in vivo* is required to facilitate further product optimization.

Patient stratification

Are there reliable biomarkers capable of predicting which patients with SR-aGVHD will respond to Ryoncil? Progress toward a personalized-medicine paradigm represents the next step in refining its clinical use.

Long-term data

Ongoing post-marketing surveillance and long-term registry studies are essential to determine the durability of response and to detect any potential late-onset adverse effects.

Global harmonization

How will other regulatory authorities (*e.g.*, EMA, PMDA) evaluate the current data? Achieving worldwide regulatory convergence is critical for ensuring equitable patient access and for streamlining subsequent product development.

CONCLUSION

The approval of Ryoncil constitutes more than a regulatory milestone; it signifies the maturation of the field of regenerative medicine. It demonstrates that, with rigorous scientific evidence, sustained development, and a collaborative resolve to address complex manufacturing and regulatory challenges, cell-based therapies can transition from promising research to standardized clinical practice.

The global impact is already apparent. Scientists now have a validated pathway for clinical translation. Regulators have a clarified framework for evaluation. Clinicians have a novel tool for their patients. Most importantly, paediatric patients with a devastating disease have a new chance at life. The Editorial Board of *Progress in Stem Cell* recognizes this event as the beginning of a new era—one where the conversation shifts from whether cell therapies can be approved to how we can develop the next products better, faster, and more equitably. The legacy of Ryoncil will be measured not only by the lives it saves directly but by the generation of therapies it enables to follow in its wake.

ABBREVIATIONS

aGVHD: acute graft-versus-host disease; **BLA:** biologics license application; **CMC:** Chemistry, Manufacturing, and Controls; **CR:** Complete Response; **CRL:** Complete Response Letter; **EMA:** European Medicines Agency; **FDA:** Food and Drug Administration; **IL-2Rα:** interleukin-2 receptor α; **MSC:** mesenchymal stromal cell; **ORR:** Overall Response Rate; **PMDA:** Pharmaceuticals and Medical Devices Agency; **PR:** Partial Response; **SR-aGVHD:** steroid-refractory acute graft-versus-host disease

ACKNOWLEDGMENTS

None.

AUTHOR'S CONTRIBUTIONS

Not applicable.

FUNDING

None.

AVAILABILITY OF DATA AND MATERIALS

Not applicable.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

CONSENT FOR PUBLICATION

Not applicable.

DECLARATION OF GENERATIVE AI AND AI-ASSISTED TECHNOLOGIES IN THE WRITING PROCESS

The authors declare that they have used generative AI and/or AI-assisted technologies in the writing process before submission, but only to improve the language and readability of their paper.

COMPETING INTERESTS

The authors declare that they have no competing interests.

REFERENCES

1. Galderisi U, Peluso G, Bernardo GD. Clinical trials based on mesenchymal stromal cells are exponentially increasing: where are we in recent years? Stem Cell Reviews and Reports. 2022;18(1):23–36. PMID: 34398443. Available from: https://doi.org/10.1007/s12015-021-10231-w.
2. Huang Y, Wu Q, Tam PK. Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications. International Journal of Molecular Sciences. 2022;23(17):10023. PMID: 36077421. Available from: https://doi.org/10.3390/ijms231710023.
3. Rodríguez-Fuentes DE, Fernández-Garza LE, Samia-Meza JA, Barrera-Barrera SA, Caplan AI, Barrera-Saldaña HA. Mesenchymal Stem Cells Current Clinical Applications: A Systematic Review. Archives of Medical Research. 2021;52(1):93–101. PMID: 32977984. Available from: https://doi.org/10.1016/j.arcmed.2020.08.006.
4. FDA Approval Letter for Ryoncil (Remestemcel-L). December 18. [Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-remestemcel-l-rknd-steroid-refractory-acute-graft-versus-host-disease-pediatric.
5. Remestemcel-L (Ryoncil) for graft-versus-host disease. The Medical Letter on Drugs and Therapeutics. 2025;67:e36–7. PMID: 39946704. Available from: https://doi.org/10.58347/tml.2025.1722i.
6. Blanc KL, Dazzi F, English K, Farge D, Galipeau J, Horwitz EM. ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells. Cytotherapy. 2025;27(4):413–6. PMID: 39864015. Available from: https://doi.org/10.1016/j.jcyt.2025.01.005.
7. Kurtzberg J, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K, et al. A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. 2020;26(5):845–54. PMID: 32018062. Available from: https://doi.org/10.1016/j.bbmt.2020.01.018.
8. Simon CG, Bozenhardt EH, Celluzzi CM, Dobnik D, Grant ML, Lakshmipathy U. Analysis of the measurements used as potency tests for the 31 US FDA-approved cell therapy products. Journal of Translational Medicine. 2025;23(1):259. PMID: 40038737. Available from: https://doi.org/10.1186/s12967-025-06253-4.